Belgian pharmaceutical company UCB (Euronext Brussels: UCB) has unveiled highlights from its forthcoming data presentations at the leading rheumatology conference, the Annual European Congress of Rheumatology (EULAR).
The company will present data on Cimzia (certolizumab pegol) and other key pipeline molecules, including bimekizumab, romosozumab, and seletalisib.
Cimzia, the company’s top-selling product, generated 1.31 billion euros ($1.5 billion) in net sales last year, a 21% rise on the year before.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze